"目錄號(hào): HY-14800
Radezolid 是一種惡唑烷酮類抗生素。
相關(guān)產(chǎn)品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-
生物活性
Description
Radezolid is a novel oxazolidinone antibiotic agent.
In Vitro
Radezolid MICs are systematically equal to or lower (up to 3 log2 dilutions) than those of linezolid for all linezolid-susceptible strains, with an 8-fold difference for the linezolid-resistant strains. Radezolid shows a greater potency than linezolid, independent of the bacteria tested, when concentrations are expressed on a weight (mg/L) basis. Radezolid shows an improved potency compared to that of linezolid when concentrations are expressed on a weight (mg/L) basis[1]. Radezolid and TR-700 perform well against 3-copy G2447T, G2576T, and G2576T/T2571C mutants[2].
Clinical Trial
Melinta Therapeutics, Inc.
Community-Acquired Pneumonia (CAP)
October 2007
Phase 2
Melinta Therapeutics, Inc.
Infectious Skin Diseases-Bacterial Skin Diseases-Staphylococcal Skin Infections-Streptococcal Infections-Abscess
December 2007
Phase 2
View MoreCollapse
References
